The recently introduced POLARx cryoballoon technology appears to have similar efficacy and safety as the Arctic Front Advance Pro for the treatment of symptomatic atrial fibrillation.
Does a novel integrated dilator and needle optimize the transseptal procedural workflow during cryoballoon ablation in patients with symptomatic atrial fibrillation?
A novel integrated dilator and needle is introduced to optimize the transseptal procedural workflow during cryoballoon ablation.
Cryoballoon ablation of the pulmonary veins (PVs) has become a common approach for the treatment of patients with symptomatic atrial fibrillation.1 The relative simplicity, fast learning curve, and lower interoperator variability have resulted in widespread adoption of this technique in clinical practice.2 Recently, a second cryoballoon technology (POLARx; Boston Scientific, Marlborough, MA) was introduced that seems to have a similar efficacy and safety as the fourth-generation Arctic Front Advance Pro (Medtronic, Minneapolis, MN).
Yap et al. (Tue,) conducted a other in symptomatic atrial fibrillation. POLARx cryoballoon technology vs. Arctic Front Advance Pro was evaluated. The recently introduced POLARx cryoballoon technology appears to have similar efficacy and safety as the Arctic Front Advance Pro for the treatment of symptomatic atrial fibrillation.